ALNYLAM PHARMACEUTICALS INC (ALNY)       219.64  -6.56 (-2.9%)

219.64  -6.56 (-2.9%)

US02043Q1076 - Common Stock - After market: 219.64 0 (0%)

ALNYLAM PHARMACEUTICALS INC219.64

NASDAQ:ALNY (12/6/2022, 7:21:00 PM)-6.56 (-2.9%)

After market: 219.64 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 10-27 2022-10-27/bmo Earnings (Next) 02-08 2023-02-08
Ins Owners 0.24% Inst Owners 104.94%
Market Cap 27.02B Shares 123.03M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 78.71
IPO 05-28 2004-05-28

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALNY Daily chart

Company Profile

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 1,665 full-time employees. The company went IPO on 2004-05-28. The company is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.

Company Info

ALNYLAM PHARMACEUTICALS INC

675 W Kendall St

Cambridge MASSACHUSETTS 02142

P: 16175518200.0

CEO: John M. Maraganore

Employees: 1665

Website: https://www.alnylam.com/

ALNY News

News Image2 days ago - Alnylam PharmaceuticalsAlnylam Anuncia a Aprovação de AMVUTTRA® (vutrisirana sódica) no Brasil para o Tratamento da Amiloidose Hereditária mediada por Transtirretina (hATTR) em Adultos

/PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), empresa líder em terapias de RNAi, acaba de anunciar que a Agência Nacional de Vigilância...

News Image6 days ago - Alnylam Pharmaceuticals, Inc.Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022News Imagea month ago - Alnylam Pharmaceuticals, Inc.Alnylam to Webcast Presentations at Upcoming November Investor ConferencesNews Imagea month ago - Alnylam Pharmaceuticals, Inc.Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive YearNews Imagea month ago - BloombergAlnylam Halts Work on Eye Drug, Citing New US Law Over Pricing

Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.

News Imagea month ago - Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

ALNY Twits

Here you can normally see the latest stock twits on ALNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example